Clinical trial • Phase I • Oncology
KITE-363 for Relapsed and refractory B-cell lymphoma
Phase I trial of KITE-363 for Relapsed and refractory B-cell lymphoma. 148 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Relapsed and refractory B-cell lymphoma
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 26-04-2024
- First CTIS Authorization Date
- 29-05-2024
Trial design
Phase I trial across 4 sites in Germany, Netherlands.
- Target Sample Size
- 148
Recruitment
- Planned Sample Size
- 148
- Recruitment Window Months
- 70
Geography
- Total Number Of Sites
- 4
- Total Number Of Participants
- 25
Germany
- Earliest CTIS Part Ii Submission Date
- 08-05-2024
- Latest Decision Or Authorization Date
- 29-04-2026
- Processing Time Days
- 721
- Number Of Sites
- 1
- Number Of Participants
- 10
Sites
- Site Name
- Universitaetsklinikum Wuerzburg AöR
- Department Name
- Medizinische Klinik Und Poliklinik II
- Principal Investigator Name
- Max Topp
- Principal Investigator Email
- topp_m@ukw.de
- Contact Person Name
- Max Topp
- Contact Person Email
- topp_m@ukw.de
Netherlands
- Earliest CTIS Part Ii Submission Date
- 08-05-2024
- Latest Decision Or Authorization Date
- 28-04-2026
- Processing Time Days
- 720
- Number Of Sites
- 3
- Number Of Participants
- 15
Sites
- Site Name
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Department Name
- Hematology
- Principal Investigator Name
- Pim Mutsaers
- Principal Investigator Email
- p.mutsaers@erasmusmc.nl
- Contact Person Name
- Pim Mutsaers
- Contact Person Email
- p.mutsaers@erasmusmc.nl
- Site Name
- Universitair Medisch Centrum Groningen
- Department Name
- Onco-Immunology Hematology
- Principal Investigator Name
- Tom van Meerten
- Principal Investigator Email
- t.van.meerten@umcg.nl
- Contact Person Name
- Tom van Meerten
- Contact Person Email
- t.van.meerten@umcg.nl
- Site Name
- Amsterdam UMC Stichting
- Department Name
- Clinical Hematology
- Principal Investigator Name
- Marie José Kersten
- Principal Investigator Email
- m.j.kersten@amsterdamumc.nl
- Contact Person Name
- Marie José Kersten
- Contact Person Email
- m.j.kersten@amsterdamumc.nl
Sponsor
Primary sponsor
- Full Name
- Kite Pharma Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- KITE-363
- Investigational Product Name
- KITE-753
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)